+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuropathic Pain Market Outlook 2026-2034: by Route of Administration (Oral, Topical, Parenteral), Drug Class, Indication, Distribution Channel- Product Image
Neuropathic Pain Market Outlook 2026-2034: by Route of Administration (Oral, Topical, Parenteral), Drug Class, Indication, Distribution Channel- Product Image
Sale

Neuropathic Pain Market Outlook 2026-2034: by Route of Administration (Oral, Topical, Parenteral), Drug Class, Indication, Distribution Channel

  • PDF Icon

    Report

  • 160 Pages
  • October 2026
  • Region: Global
  • OG Analysis
  • ID: 6242821
UP TO OFF until Jan 01st 2027
Description Jump to:
The Neuropathic Pain Market is estimated at US$7.9 billion in 2026 and is projected to grow at a CAGR of 7.9% to reach US$14.5 billion by 2034.

Market Overview

The Neuropathic Pain Market covers therapies and supportive care approaches used to treat chronic pain arising from nerve damage, dysfunction, or disease across multiple indications.

Relevant uses and settings include pain clinics, neurology treatment, diabetes related care, oncology support, hospital use, retail pharmacy, and long term symptom management. Commercial considerations include variable patient response, side effect concerns, payer scrutiny, and limited differentiation among some established pain treatment classes.

Market Segmentation

By Route of Administration

  • Oral
  • Topical
  • Parenteral

By Drug Class

  • Anticonvulsants
  • Serotonin and Norepinephrine Reuptake Inhibitors
  • Tricyclic Antidepressant
  • Opioids
  • Topical Agents
  • Other Classes

By Indication

  • Diabetic Peripheral Neuropathy
  • Postherpetic Neuralgia
  • Chemotherapy-Induced Peripheral Neuropathy
  • Trigeminal Neuralgia
  • HIV-Associated Neuropathy
  • Phantom Limb Pain
  • Others (MS, Spinal Cord Injury)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Key Companies Analysed

  • Pfizer
  • Eli Lilly
  • AbbVie
  • Teva Pharmaceutical Industries
  • Novartis
  • Merck & Co.
  • Viatris
  • Sun Pharmaceutical
  • Dr. Reddy's Laboratories
  • Astellas Pharma
  • UCB
  • Bausch Health
  • GSK
  • Sanofi
  • Johnson & Johnson
  • Lundbeck
  • Otsuka Pharmaceutical
  • Eisai
  • Torrent Pharmaceuticals
  • Zydus Lifesciences

Geographic Coverage

  • North America - Market data and outlook to 2034
    • United States
    • Canada
    • Mexico

  • Europe - Market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Netherlands
    • Switzerland
    • Poland
    • Sweden
    • Russia

  • Asia-Pacific - Market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam

  • Middle East and Africa - Market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt

  • South and Central America - Market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru

*We can include data and analysis of additional countries on demand.

Report Delivery and Support

  • Updated PDF report and an MS Excel workbook containing market tables and figures.
  • 7-day post-sale analyst support for clarifications and in-scope supplementary data.
  • Complimentary report update covering the latest available data and relevant market developments.

This product will be delivered within 1-3 business days.

Table of Contents

1. Contents and Report Guide
1.1. List of Tables
1.2. List of Figures
2. Global Neuropathic Pain Market Overview
2.1. Neuropathic Pain Market Scope and Definitions
2.2. Research Methodology and Forecast Assumptions
2.3. Value Chain and Relevant Adjacent Markets
3. Neuropathic Pain Market Dynamics
3.1. Demand Drivers
3.2. Constraints and Adoption Barriers
3.3. Technology and Commercial Trends
3.4. Regulatory and Supply-Chain Considerations
4. Neuropathic Pain Market Strategic Analysis
4.1. Competitive Structure
4.2. Pricing and Purchasing Factors
4.3. Customer Requirements and Opportunity Assessment
5. Global Neuropathic Pain Market Size, Share and Forecast, 2025-2034
5.1. Revenue Outlook, 2025-2034 (US$ billion)
5.2. Neuropathic Pain Market Analysis By Route of Administration, 2025-2034
5.2.1. Oral
5.2.2. Topical
5.2.3. Parenteral
5.3. Neuropathic Pain Market Analysis By Drug Class, 2025-2034
5.3.1. Anticonvulsants
5.3.2. Serotonin and Norepinephrine Reuptake Inhibitors
5.3.3. Tricyclic Antidepressant
5.3.4. Opioids
5.3.5. Topical Agents
5.3.6. Other Classes
5.4. Neuropathic Pain Market Analysis By Indication, 2025-2034
5.4.1. Diabetic Peripheral Neuropathy
5.4.2. Postherpetic Neuralgia
5.4.3. Chemotherapy-Induced Peripheral Neuropathy
5.4.4. Trigeminal Neuralgia
5.4.5. HIV-Associated Neuropathy
5.4.6. Phantom Limb Pain
5.4.7. Others (MS, Spinal Cord Injury)
5.5. Neuropathic Pain Market Analysis By Distribution Channel, 2025-2034
5.5.1. Hospital Pharmacies
5.5.2. Retail Pharmacies
5.5.3. Online Pharmacies
6. North America Neuropathic Pain Market Outlook to 2034
6.1. North America Market Snapshot
6.2. North America Neuropathic Pain Market Analysis By Route of Administration
6.3. North America Neuropathic Pain Market Analysis By Drug Class
6.4. North America Neuropathic Pain Market Analysis By Indication
6.5. North America Neuropathic Pain Market Analysis By Distribution Channel
6.6. North America Outlook By Country
6.6.1. United States
6.6.2. Canada
6.6.3. Mexico
7. Europe Neuropathic Pain Market Outlook to 2034
7.1. Europe Market Snapshot
7.2. Europe Neuropathic Pain Market Analysis By Route of Administration
7.3. Europe Neuropathic Pain Market Analysis By Drug Class
7.4. Europe Neuropathic Pain Market Analysis By Indication
7.5. Europe Neuropathic Pain Market Analysis By Distribution Channel
7.6. Europe Outlook By Country
7.6.1. Germany
7.6.2. United Kingdom
7.6.3. France
7.6.4. Italy
7.6.5. Spain
7.6.6. Netherlands
7.6.7. Switzerland
7.6.8. Poland
7.6.9. Sweden
7.6.10. Russia
8. Asia-Pacific Neuropathic Pain Market Outlook to 2034
8.1. Asia-Pacific Market Snapshot
8.2. Asia-Pacific Neuropathic Pain Market Analysis By Route of Administration
8.3. Asia-Pacific Neuropathic Pain Market Analysis By Drug Class
8.4. Asia-Pacific Neuropathic Pain Market Analysis By Indication
8.5. Asia-Pacific Neuropathic Pain Market Analysis By Distribution Channel
8.6. Asia-Pacific Outlook By Country
8.6.1. China
8.6.2. Japan
8.6.3. India
8.6.4. South Korea
8.6.5. Australia
8.6.6. Indonesia
8.6.7. Malaysia
8.6.8. Vietnam
9. Middle East and Africa Neuropathic Pain Market Outlook to 2034
9.1. Middle East and Africa Market Snapshot
9.2. Middle East and Africa Neuropathic Pain Market Analysis By Route of Administration
9.3. Middle East and Africa Neuropathic Pain Market Analysis By Drug Class
9.4. Middle East and Africa Neuropathic Pain Market Analysis By Indication
9.5. Middle East and Africa Neuropathic Pain Market Analysis By Distribution Channel
9.6. Middle East and Africa Outlook By Country
9.6.1. Saudi Arabia
9.6.2. South Africa
9.6.3. Iran
9.6.4. United Arab Emirates
9.6.5. Egypt
10. South and Central America Neuropathic Pain Market Outlook to 2034
10.1. South and Central America Market Snapshot
10.2. South and Central America Neuropathic Pain Market Analysis By Route of Administration
10.3. South and Central America Neuropathic Pain Market Analysis By Drug Class
10.4. South and Central America Neuropathic Pain Market Analysis By Indication
10.5. South and Central America Neuropathic Pain Market Analysis By Distribution Channel
10.6. South and Central America Outlook By Country
10.6.1. Brazil
10.6.2. Argentina
10.6.3. Chile
10.6.4. Peru
11. Neuropathic Pain Market Competitive Landscape
11.1. Market Participants and Strategic Positioning
11.2. Company Profiles: Product Portfolios, Positioning and Strategies
11.2.1. Pfizer
11.2.2. Eli Lilly
11.2.3. AbbVie
11.2.4. Teva Pharmaceutical Industries
11.2.5. Novartis
11.2.6. Merck & Co.
11.2.7. Viatris
11.2.8. Sun Pharmaceutical
11.2.9. Dr. Reddy's Laboratories
11.2.10. Astellas Pharma
11.2.11. UCB
11.2.12. Bausch Health
11.2.13. GSK
11.2.14. Sanofi
11.2.15. Johnson & Johnson
11.2.16. Lundbeck
11.2.17. Otsuka Pharmaceutical
11.2.18. Eisai
11.2.19. Torrent Pharmaceuticals
11.2.20. Zydus Lifesciences
12. Appendix
12.1. Definitions and Abbreviations
12.2. Data Sources and Methodology
12.3. Publisher Information

Companies Mentioned

  • Pfizer
  • Eli Lilly
  • AbbVie
  • Teva Pharmaceutical Industries
  • Novartis
  • Merck & Co.
  • Viatris
  • Sun Pharmaceutical
  • Dr. Reddy's Laboratories
  • Astellas Pharma
  • UCB
  • Bausch Health
  • GSK
  • Sanofi
  • Johnson & Johnson
  • Lundbeck
  • Otsuka Pharmaceutical
  • Eisai
  • Torrent Pharmaceuticals
  • Zydus Lifesciences

Table Information

Report AttributeDetails
No. of Pages160
PublishedOctober 2026
Forecast Period2026 - 2034
Estimated Market Value ( USD ) in 2026 $ 7.9 Billion
Forecasted Market Value ( USD ) by 2034 $ 14.5 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Neuropathic Pain Market Report 2026 - Product Image

Neuropathic Pain Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Peripheral Neuropathic Pain Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, Application, Distribution Channel, and Region, 2025-2035 - Product Image

Peripheral Neuropathic Pain Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, Application, Distribution Channel, and Region, 2025-2035

  • Report
  • Global
From
Diabetic Neuropathic Pain Market - A Global and Regional Analysis: Focus on Type, Distribution Channel, and Region, 2025-2035 - Product Image

Diabetic Neuropathic Pain Market - A Global and Regional Analysis: Focus on Type, Distribution Channel, and Region, 2025-2035

  • Report
  • Global
From
Neuropathic Pain Market Size, Share & Trends Analysis Report by Drug Class,, Indication, Route of Administration, Distribution Channel, Region, and Growth Forecasts, 2026-2033 - Product Image

Neuropathic Pain Market Size, Share & Trends Analysis Report by Drug Class,, Indication, Route of Administration, Distribution Channel, Region, and Growth Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Neuropathic Pain Drug Market - Global Forecast 2026-2032 - Product Image

Neuropathic Pain Drug Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.